Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UMPS | P11172 | 5/20 | 0.48 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.45 |
| ▸ | GART | P22102 | 1/20 | 0.45 |
| ▸ | ATIC | P31939 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803212 | 1.00 | UMPS (0.48) | UMPSDNPH1FBP1TAS1R3TAS1R1 | |
| SCHEMBL17010785 | 1.00 | UMPS (0.48) | UMPSDNPH1FBP1TAS1R3TAS1R1 | |
| SCHEMBL15277191 | 1.00 | UMPS (0.48) | UMPSDNPH1FBP1TAS1R3TAS1R1 | |
| SCHEMBL18999742 | 1.00 | UMPS (0.48) | UMPSDNPH1FBP1TAS1R3TAS1R1 | |
| SCHEMBL15257897 | 1.00 | UMPS (0.48) | UMPSDNPH1FBP1TAS1R3TAS1R1 | |
| SCHEMBL25458670 | 0.90 | P2RY2 (0.53) | P2RY2P2RY6 | |
| SCHEMBL18999749 | 0.90 | P2RY2 (0.53) | P2RY2P2RY6 | |
| SCHEMBL15702884 | 0.87 | P2RY2 (0.54) | P2RY2P2RY6 | |
| SCHEMBL26396048 | 0.84 | P2RY6 (0.46) | P2RY2P2RY6 | |
| SCHEMBL16489871 | 0.82 | P2RX1 (0.40) | UMPSDNPH1TAS1R3TAS1R1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150050354-A1 | MODIFIED POLYNUCLEOTIDES FOR THE TREATMENT OF OTIC DISEASES AND CONDITIONS | MODERNATX, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150044277-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CASPASE 3 | MODERNA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044277-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CASPASE 3 | CASP3, POLRMT, NSUN3 | UMPS 502/4885DNPH1 2649/4885FBP1 3993/4885 |
| US-20150050354-A1 | MODIFIED POLYNUCLEOTIDES FOR THE TREATMENT OF OTIC DISEASES AND CONDITIONS | OTC, POLRMT, POLN | UMPS 174/4885DNPH1 3462/4885FBP1 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.